IMMATICS BIOTECHNOLOGIES

We have a big goal: overcome the challenges of fighting cancer and bring new therapeutic products to cancer patients. We do this with a singular passion and relentless focus to achieve better outcomes for patients... This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer... Immatics has identified and characterized a trove of novel intracellular tumor targets for the development of cancer immunotherapies. We use this knowledge together with our XPRESIDENT® technology to define true targets, distinct molecular barcodes that identify the tumor cell. This gives us a drug discovery advantage that we aim to leverage for our own proprietary pipeline and for our collaborations with world-leading partners.

Also known as: Immatics Biotechnologies GmbH

Registration numbers: HRB 382151 (W)

VAT numbers: DE813106208

Primary location: Munich Germany